Ultima-Stan 25 Mg 50 Tablets Ultima Pharma USA
$109.00
Product Short Description
Ultima-Stan 25 mg 50 Tablets Ultima Pharma USA delivers stanozolol (C21H32N2O), the pyrazole-fused DHT anabolic steroid exhibiting high anabolic potency (~320:30 ratio), at balanced oral 25 mg strength bridging prescription and institutional formats. Domestic production serves DEA Schedule III compliant channels exclusively.
Product Overview
Ultima Pharma USA’s Stan 25 mg presents stanozolol, featuring C2-C3 pyrazole substitution preventing aromatization characteristic of 17α-methylated DHT derivatives (~8-hour half-life), in USP-equivalent scored tablets for institutional catalogs. The 50-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring batch traceability essential for DEA-regulated workflows.
U.S. domestic manufacturing eliminates customs exposure distinguishing legitimate Schedule III supply from underground tablet presses prevalent in non-verified markets. Intermediate dosage serves advanced resellers managing controlled substance inventories balancing potency and safety margins.
Ultima-Stan targets verified CIII ecosystems emphasizing commercial positioning without protocols or claims.
Brand & Manufacturer Information
Ultima Pharma USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. Stan 25 mg maintains catalog continuity alongside Ultima-Stan 50 mg and Superdrol authenticating legitimate institutional supply versus powder-converted alternatives.
Active Compound Information
Contains stanozolol (17α-methyl-2’H-5α-androst-2-enopyrazol-17β-ol), heterocyclic DHT derivative enabling high anabolic:androgenic dissociation with no estrogen conversion and moderate hepatotoxicity profile characteristic of 17α-methylated oral steroids. DEA Schedule III (21 CFR 1308.13) reflects performance dosage potential.
25 mg strength represents balanced institutional dosing. WADA S1a prohibited globally.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Ultima-Stan 25 mg 50 Tablets Ultima Pharma USA |
| Active Compound | Stanozolol (C21H32N2O) |
| Strength | 25 mg per scored tablet |
| Quantity | 50 tablets per bottle |
| Form | Oral scored tablets |
| Category | DEA Schedule III controlled substance |
| Packaging | Tamper-evident HDPE bottle |
Quality Control & Testing Standards
25 mg stanozolol mandates USP potency assay (90-110% HPLC), dissolution profiling, and uniformity verification confirming pharmaceutical-grade content. Ultima batch documentation verifies C21H32N2O identity distinguishing legitimate production from underground alternatives.
50-tablet institutional bottling prevents diversion matching DEA protocols.
Legal & Regulatory Disclaimer
Stanozolol constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.